Patrice D. Cani, Marco Peters, Dominic J. Withers, Rachel L. Batterham, Alan Ashworth, Claude Knauf, Anne White, Rémy Burcelin, Philippe Valet, André Colom, Kaisa Piipari, Hind Al-Qassab, Angela Woods, K. Peter Giese, Ghazala Begum, Amanda Heslegrave, Michael L.J. Ashford, Mark A. Smith, Marc Claret, Keiko Mizuno, Phillip Mucket, David Carling, Julian J. Emmanuel, Laboratory of Diabetes and Obesity, Endocrinology and Nutrition Unit, Hospital Clínic de Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer, Metabolic Signalling Group, Imperial College London-Clinical Sciences Centre-Medical Research Council (MRC), Biomedical Research Institute, University of Dundee-Ninewells Hospital and Medical School [Dundee], Institut de médecine moléculaire de Rangueil (I2MR), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-IFR150-Institut National de la Santé et de la Recherche Médicale (INSERM), Cellular Stress Group, Centre for Diabetes and Endocrinology, University College of London [London] (UCL)-Rayne Institute, Unit of Pharmacokinetics, Metabolism, Nutrition, and Toxicology, Université Catholique de Louvain = Catholic University of Louvain (UCL)-Louvain Drug Research Institute, Manchester Academic Health Sciences Centre, University of Manchester [Manchester]-Faculties of Life Sciences and Medical and Human Sciences, Centre for the Cellular Basis of Behaviour, Institute of psychiatry-King‘s College London, The Breakthrough Breast Cancer Research Centre, Institute of cancer research, This work was supported by grants from the Biotechnology and Biological Sciences Research Council (to D.J.W.), the Medical Research Council (to D.J.W., R.L.B., K.P.G., and D.C.), the Wellcome Trust (to D.J.W., K.P.G., and M.L.A.), and the European Commission (contract no. LSHM-CT-2004-005272, to D.C.). M.C. is a recipient of a Miguel Servet contract (CP09/00233) from the Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación (Spain)., UCL - SSS/LDRI - Louvain Drug Research Institute, Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées- Institut Fédératif de Recherche Bio-médicale Institution (IFR150)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Simon, Marie Francoise
OBJECTIVE AMP-activated protein kinase (AMPK) signaling acts as a sensor of nutrients and hormones in the hypothalamus, thereby regulating whole-body energy homeostasis. Deletion of Ampkα2 in pro-opiomelanocortin (POMC) neurons causes obesity and defective neuronal glucose sensing. LKB1, the Peutz-Jeghers syndrome gene product, and Ca2+-calmodulin–dependent protein kinase kinase β (CaMKKβ) are key upstream activators of AMPK. This study aimed to determine their role in POMC neurons upon energy and glucose homeostasis regulation. RESEARCH DESIGN AND METHODS Mice lacking either Camkkβ or Lkb1 in POMC neurons were generated, and physiological, electrophysiological, and molecular biology studies were performed. RESULTS Deletion of Camkkβ in POMC neurons does not alter energy homeostasis or glucose metabolism. In contrast, female mice lacking Lkb1 in POMC neurons (PomcLkb1KO) display glucose intolerance, insulin resistance, impaired suppression of hepatic glucose production, and altered expression of hepatic metabolic genes. The underlying cellular defect in PomcLkb1KO mice involves a reduction in melanocortin tone caused by decreased α-melanocyte–stimulating hormone secretion. However, Lkb1-deficient POMC neurons showed normal glucose sensing, and body weight was unchanged in PomcLkb1KO mice. CONCLUSIONS Our findings demonstrate that LKB1 in hypothalamic POMC neurons plays a key role in the central regulation of peripheral glucose metabolism but not body-weight control. This phenotype contrasts with that seen in mice lacking AMPK in POMC neurons with defects in body-weight regulation but not glucose homeostasis, which suggests that LKB1 plays additional functions distinct from activating AMPK in POMC neurons.